Although palbociclib was believed to exhibit anti-cancer potencies in an RB-dependent manner, increasing evidences showed that another potential biomarker was necessary for the response of RB-proficient cancer cells to palbociclib [23]. The gene discussed is RB1; the disease is cancer.